Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions
dc.contributor.author | Rej, Rohan Kalyan | |
dc.contributor.author | Roy, Joyeeta | |
dc.contributor.author | Allu, Srinivasa Rao | |
dc.date.accessioned | 2024-02-01T01:10:13Z | |
dc.date.available | 2024-02-01T01:10:13Z | |
dc.date.issued | 2024-01-27 | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/192163 | |
dc.description.abstract | <jats:p>The hormone receptor-positive (HR+) type is the most frequently identified subtype of breast cancer. HR+ breast cancer has a more positive prognosis when compared to other subtypes, such as human epidermal growth factor protein 2-positive disorder and triple-negative disease. The advancement in treatment outcomes for advanced HR+ breast cancer has been considerably elevated due to the discovery of cyclin-dependent kinase 4/6 inhibitors and their combination effects with endocrine therapy. However, despite the considerable effectiveness of tamoxifen, a selective estrogen receptor modulator (SERMs), and aromatase inhibitors (AI), the issue of treatment resistance still presents a significant challenge for HR+ breast cancer. As a result, there is a focus on exploring new therapeutic strategies such as targeted protein degradation and covalent inhibition for targeting ERα. This article discusses the latest progress in treatments like oral selective ER degraders (SERDs), complete estrogen receptor antagonists (CERANs), selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimera (PROTAC) degraders, and combinations of CDK4/6 inhibitors with endocrine therapy. The focus is specifically on those compounds that have transitioned into phases of clinical development.</jats:p> | |
dc.language | en | |
dc.publisher | MDPI AG | |
dc.title | Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions | |
dc.type | Article | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/192163/2/cancers-16-00552-v2 (1).pdf | |
dc.identifier.doi | 10.3390/cancers16030552 | |
dc.identifier.doi | https://dx.doi.org/10.7302/22163 | |
dc.identifier.source | Cancers | |
dc.description.version | Published online | |
dc.date.updated | 2024-02-01T01:10:09Z | |
dc.identifier.orcid | 0000-0003-0904-9137 | |
dc.identifier.orcid | 0000-0001-9178-2578 | |
dc.identifier.volume | 16 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 552 | |
dc.identifier.endpage | 552 | |
dc.identifier.name-orcid | Rej, Rohan Kalyan; 0000-0003-0904-9137 | |
dc.identifier.name-orcid | Roy, Joyeeta | |
dc.identifier.name-orcid | Allu, Srinivasa Rao; 0000-0001-9178-2578 | |
dc.working.doi | 10.7302/22163 | en |
dc.owningcollname | Internal Medicine, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.